Evidence map›Paper›PMID 31922007›Full record

ArticleScience advances2020

Heparin-mediated delivery of bone morphogenetic protein-2 improves spatial localization of bone regeneration.

Marian H Hettiaratchi, Laxminarayanan Krishnan, Tel Rouse, Catherine Chou, Todd C McDevitt, Robert E Guldberg

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 1 synthesis or guideline pooled it, 133 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Marian H HettiaratchiThe Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30322, USA.ORCID 0000-0001-8187-4575
Laxminarayanan KrishnanThe Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30322, USA.ORCID 0000-0002-3519-5341
Tel RouseThe Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30322, USA.ORCID 0000-0001-6546-9772
Catherine ChouThe Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30322, USA.ORCID 0000-0003-2818-5599
Todd C McDevittThe Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA.ORCID 0000-0002-8905-4931
Robert E GuldbergThe Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30322, USA.ORCID 0000-0002-0303-261X
Georgia Institute of Technology · USGladstone Institutes · US

Funding

Stem Cell Morphogen Delivery via Engineered BiomaterialsR01AR062006 · NIAMS · J. DAVID GLADSTONE INSTITUTES · PI MCDEVITT, TODD C · 2011 to 2015
$1.9M
IVIS Spectrum in vivo Imaging SystemS10OD016264 · OD · GEORGIA INSTITUTE OF TECHNOLOGY · PI GARCIA, ANDRES J · 2015 to 2015
$595k
NIAMS NIH HHS R01 AR062006NIH HHS S10 OD016264
6 · The paper itself

Abstract

Supraphysiologic doses of bone morphogenetic protein-2 (BMP-2) are used clinically to promote bone formation in fracture nonunions, large bone defects, and spinal fusion. However, abnormal bone formation (i.e., heterotopic ossification) caused by rapid BMP-2 release from conventional collagen sponge scaffolds is a serious complication. We leveraged the strong affinity interactions between heparin microparticles (HMPs) and BMP-2 to improve protein delivery to bone defects. We first developed a computational model to investigate BMP-2-HMP interactions and demonstrated improved in vivo BMP-2 retention using HMPs. We then evaluated BMP-2-loaded HMPs as a treatment strategy for healing critically sized femoral defects in a rat model that displays heterotopic ossification with clinical BMP-2 doses (0.12 mg/kg body weight). HMPs increased BMP-2 retention in vivo, improving spatial localization of bone formation in large bone defects and reducing heterotopic ossification. Thus, HMPs provide a promising opportunity to improve the safety profile of scaffold-based BMP-2 delivery.

Indexed as

Drug Delivery SystemsAnimalsBone Morphogenetic Protein 2Bone RegenerationCollagenFemurHeparinHumansOssification, HeterotopicOsteogenesisRatsRecombinant ProteinsTransforming Growth Factor betaX-Ray MicrotomographyBMP2 protein, humanBone Morphogenetic Protein 2CollagenHeparinRecombinant ProteinsTransforming Growth Factor beta

Identifiers

PMID31922007
PMCPMC6941907
OpenAlexW2998236767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.